{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:09:11Z","timestamp":1784300951346,"version":"3.55.0"},"reference-count":147,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010949","name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research","doi-asserted-by":"publisher","award":["Not applicable."],"award-info":[{"award-number":["Not applicable."]}],"id":[{"id":"10.13039\/501100010949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ EBM"],"accepted":{"date-parts":[[2021,10,13]]},"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the beneficial and harmful effects of adding ivabradine to usual care in participants with heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A systematic review with meta-analysis and trial sequential analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>Randomised clinical trials comparing ivabradine and usual care with usual care (with or without) placebo in participants with heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Information sources<\/jats:title>\n                    <jats:p>Medline, Embase, CENTRAL, LILACS, CNKI, VIP and other databases and trial registries up until 31 May 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction<\/jats:title>\n                    <jats:p>Primary outcomes were all-cause mortality, serious adverse events and quality of life. Secondary outcomes were cardiovascular mortality, myocardial infarction and non-serious adverse events. We performed meta-analysis of all outcomes. We used trial sequential analysis to control risks of random errors, the Cochrane risk of bias tool to assess the risks of systematic errors and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) to assess the certainty of the evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 109 randomised clinical trials with 26\u2009567 participants. Two trials were at low risk of bias, although both trials were sponsored by the company that developed ivabradine. All other trials were at high risk of bias. Meta-analyses and trial sequential analyses showed that we could reject that ivabradine versus control reduced all-cause mortality (risk ratio (RR)=0.94; 95%\u2009CI 0.88 to 1.01; p=0.09; high certainty of evidence). Meta-analysis and trial sequential analysis showed that ivabradine seemed to reduce the risk of serious adverse events (RR=0.90; 95%\u2009CI 0.87 to 0.94; p&lt;0.00001; number needed to treat (NNT)=26.2; low certainty of evidence). This was primarily due to a decrease in the risk of \u2018cardiac failure\u2019 (RR=0.83; 95%\u2009CI 0.71 to 0.97; p=0.02; NNT=43.9), \u2018hospitalisations\u2019 (RR=0.89; 95%\u2009CI 0.85 to 0.94; p&lt;0.0001; NNT=36.4) and \u2018ventricular tachycardia\u2019 (RR=0.59; 95%\u2009CI 0.43 to 0.82; p=0.001; NNT=212.8). However, the trials did not describe how these outcomes were defined and assessed during follow-up. Meta-analyses showed that ivabradine increased the risk of atrial fibrillation (RR=1.19; 95%\u2009CI 1.04 to 1.35; p=0.008; number needed to harm (NNH)=116.3) and bradycardia (RR=3.95; 95%\u2009CI 1.88 to 8.29; p=0.0003; NNH=303). Ivabradine seemed to increase quality of life on the Kansas City Cardiomyopathy Questionnaire (KCCQ) (mean difference (MD)=2.92; 95%\u2009CI 1.34 to 4.50; p=0.0003; low certainty of evidence), but the effect size was small and possibly without relevance to patients, and on the Minnesota Living With Heart Failure Questionnaire (MLWHFQ) (MD=\u22125.28; 95%\u2009CI \u22126.60 to \u22123.96; p&lt;0.00001; very low certainty of evidence), but the effects were uncertain. Meta-analysis showed no evidence of a difference between ivabradine and control when assessing cardiovascular mortality and myocardial infarction. Ivabradine seemed to increase the risk of non-serious adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and relevance<\/jats:title>\n                    <jats:p>High certainty evidence shows that ivabradine does not seem to affect the risks of all-cause mortality and cardiovascular mortality. The effects on quality of life were small and possibly without relevance to patients on the KCCQ and were very uncertain for the MLWHFQ. The effects on serious adverse events, myocardial infarction and hospitalisation are uncertain. Ivabradine seems to increase the risk of atrial fibrillation, bradycardia and non-serious adverse events.<\/jats:p>\n                    <jats:p>PROSPERO registration number: CRD42018112082.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjebm-2021-111724","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T13:37:47Z","timestamp":1637156267000},"page":"224-234","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Ivabradine added to usual care in patients with heart failure: a systematic review with meta-analysis and trial sequential analysis"],"prefix":"10.1136","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9037-7295","authenticated-orcid":false,"given":"Mathias","family":"Maagaard","sequence":"first","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1108-9533","authenticated-orcid":false,"given":"Emil Eik","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Copenhagen, Denmark"},{"name":"Department of Internal Medicine, Holbaek Sygehus, Holbaek, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8025-1939","authenticated-orcid":false,"given":"Naqash Javaid","family":"Sethi","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0260-2331","authenticated-orcid":false,"given":"Ning","family":"Liang","sequence":"additional","affiliation":[{"name":"Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China"},{"name":"China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6767-9826","authenticated-orcid":false,"given":"Si-Hong","family":"Yang","sequence":"additional","affiliation":[{"name":"China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8861-0799","authenticated-orcid":false,"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Copenhagen, Denmark"},{"name":"Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3642-2120","authenticated-orcid":false,"given":"Janus Christian","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Copenhagen, Denmark"},{"name":"Department of Regional Health Research, The Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"2026071707551047000_27.4.224.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61682-2"},{"key":"2026071707551047000_27.4.224.2","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-019-0957-0","article-title":"Ivabradine for coronary artery disease and\/or heart failure-a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis","volume":"8","author":"Maagaard","year":"2019","journal-title":"Syst Rev"},{"key":"2026071707551047000_27.4.224.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31829e8776"},{"key":"2026071707551047000_27.4.224.4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"2026071707551047000_27.4.224.5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"2026071707551047000_27.4.224.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.04.025"},{"key":"2026071707551047000_27.4.224.7","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016631571"},{"key":"2026071707551047000_27.4.224.8","first-page":"810","article-title":"Ivabradine (Corlanor) for heart failure: the first selective and specific I F inhibitor","volume":"40","author":"Tse","year":"2015","journal-title":"P T"},{"key":"2026071707551047000_27.4.224.9","article-title":"Ivabradine as adjuvant treatment for chronic heart failure","volume":"11","author":"Benstoem","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2026071707551047000_27.4.224.10","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1536\/ihj.18-559","article-title":"Ivabradine improves cardiac function and increases exercise capacity in patients with chronic heart failure","volume":"60","author":"Pei","year":"2019","journal-title":"Int Heart J"},{"key":"2026071707551047000_27.4.224.11","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0315-7"},{"key":"2026071707551047000_27.4.224.12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-10-90"},{"key":"2026071707551047000_27.4.224.13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-120"},{"key":"2026071707551047000_27.4.224.14","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2026071707551047000_27.4.224.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"2026071707551047000_27.4.224.16","unstructured":"Maagaard M , Nielsen EE , Gluud C . Ivabradine for coronary artery disease and\/or heart failure: a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. prospero 2018 CRD42018112082, 2018. Available: http:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?ID=CRD42018112082"},{"key":"2026071707551047000_27.4.224.17","unstructured":"Higgins JP , Green S . Cochrane Handbook for systematic reviews of interventions, 2011. Available: www.cochrane-handbook.org"},{"key":"2026071707551047000_27.4.224.18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3"},{"key":"2026071707551047000_27.4.224.19","unstructured":"Review manager (RevMan), 2014. Available: https:\/\/training.cochrane.org\/online-learning\/core-software-cochrane-reviews\/revman\/revman-5-download"},{"key":"2026071707551047000_27.4.224.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61170-8"},{"key":"2026071707551047000_27.4.224.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61198-1"},{"key":"2026071707551047000_27.4.224.22","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyn179"},{"key":"2026071707551047000_27.4.224.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-011890"},{"key":"2026071707551047000_27.4.224.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2026071707551047000_27.4.224.25","unstructured":"Sch\u00fcnemann H , Bro\u017cek J , Guyatt G . Grade Handbook for grading quality of evidence and strength of recommendations, 2013. Available: https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"key":"2026071707551047000_27.4.224.26","doi-asserted-by":"crossref","unstructured":"Abdel Hady YA . Effects of adding ivabradine to optimal medical therapy in symptomatic patients with left ventricular systolic dysfunction secondary to ischemic or idiopathic dilated cardiomyopathy. Eur J Heart Fail doi:10.1093\/eurjhf\/hsr015","DOI":"10.1093\/eurjhf\/hsr015"},{"key":"2026071707551047000_27.4.224.27","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5603\/CJ.a2014.0057","article-title":"I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life","volume":"22","author":"Abdel-Salam","year":"2015","journal-title":"Cardiol J"},{"key":"2026071707551047000_27.4.224.28","first-page":"E341","article-title":"Addition of ivabradin further improves clinical status in patients with end stage heart failure and intolerance to ss-blockers","volume":"118","author":"Adamyan","year":"2008","journal-title":"Circulation"},{"key":"2026071707551047000_27.4.224.29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp534"},{"key":"2026071707551047000_27.4.224.30","first-page":"666","article-title":"Efficacy of long-term ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved left ventricular systolic function","volume":"36","author":"Adamyan","year":"2015","journal-title":"European Heart Journal"},{"key":"2026071707551047000_27.4.224.31","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2013.07.205","article-title":"PP166\u2014Effect of carvedilol versus Carvedilol\/Ivabradine combination on heart rate, quality of life, morbidity and mortality in patients with stable ischemic heart failure","volume":"35","author":"Al Saadi","year":"2013","journal-title":"Clin Ther"},{"key":"2026071707551047000_27.4.224.32","article-title":"Prognosis of heart rate control on decompensated heart failure patients","volume":"118","author":"Aroutunov","year":"2008","journal-title":"Circulation"},{"key":"2026071707551047000_27.4.224.33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.18087\/cardio.2020.10.n1324","article-title":"[Ivabradine for Treatment of Heart Failure with Preserved Ejection Fraction]","volume":"60","author":"Babushkina","year":"2020","journal-title":"Kardiologiia"},{"key":"2026071707551047000_27.4.224.34","article-title":"Importance of serum sodium in ischemic heart failure with systolic dysfunction","volume":"21","author":"Bansal","year":"2019","journal-title":"European Journal of Heart Failure"},{"key":"2026071707551047000_27.4.224.35","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40261-016-0424-9","article-title":"Ivabradine in patients with ST-elevation myocardial infarction complicated by cardiogenic shock: a preliminary randomized prospective study","volume":"36","author":"Barill\u00e0","year":"2016","journal-title":"Clin Drug Investig"},{"key":"2026071707551047000_27.4.224.36","first-page":"1529","article-title":"Effect of ivabradine on serum NT-proBNP MMP-9 in patients with chronic heart failure","volume":"24","author":"Bi","year":"2020","journal-title":"The Medical Forum"},{"key":"2026071707551047000_27.4.224.37","first-page":"1217","article-title":"Effects of ivabradine on serum cyclophilin A and copeptin in patients with chronic congestive heart failure","volume":"33","author":"Cao","year":"2019","journal-title":"Practical Geriatrics"},{"key":"2026071707551047000_27.4.224.38","article-title":"Dobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure","volume":"33","author":"Cavusoglu","year":"2012","journal-title":"European Heart Journal"},{"key":"2026071707551047000_27.4.224.39","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.ihj.2014.10.232","article-title":"Effects of ivabradine on left ventricular function in patients with ischemic heart failure","volume":"66","author":"Chaudhari","year":"2014","journal-title":"Indian Heart J"},{"key":"2026071707551047000_27.4.224.40","first-page":"2860","article-title":"Effect of ivabradine on serum NT-proBNP left ventricular ejection fraction and heart rate variability in patients with chronic heart failure","volume":"24","author":"Chen","year":"2020","journal-title":"The Medical Forum"},{"key":"2026071707551047000_27.4.224.41","first-page":"16","article-title":"Pharmacologic observation of ivabradine in the treatment of moderate to severe chronic heart failure combined with sinus tachycardia","volume":"37","author":"Chen","year":"2021","journal-title":"Chinese Community Doctors"},{"key":"2026071707551047000_27.4.224.42","article-title":"Effectiveness of ivabradine combined with levosimendan for treating chronic heart failure","volume":"7","author":"Chen","year":"2021","journal-title":"Frontiers of Medicine"},{"key":"2026071707551047000_27.4.224.43","first-page":"589","article-title":"Observation on curative efficacy and safety of ivabradine combined with routine treatment of chronic heart failure","volume":"26","author":"Cheng","year":"2017","journal-title":"Chinese Journal of Pharmacoepidemiology"},{"key":"2026071707551047000_27.4.224.44","article-title":"Efficacy and safety of ivabradin treatment in patients with dilated cardiomyopathy","volume":"12","author":"Chumburidze","year":"2013","journal-title":"European Journal of Heart Failure"},{"key":"2026071707551047000_27.4.224.45","first-page":"113","article-title":"Evaluation of the efficacy of ivabradine in the treatment of chronic systolic heart failure","volume":"13","author":"Cong","year":"2018","journal-title":"Chinese Practical Medicine"},{"key":"2026071707551047000_27.4.224.46","first-page":"77","article-title":"Efficacy and adverse reactions of ivabradine in the treatment of chronic heart failure","volume":"11","author":"Deng","year":"2017","journal-title":"The World Clinical Medicine"},{"key":"2026071707551047000_27.4.224.47","first-page":"3613","article-title":"Clinical study of ivabradine combined with metoprolol in the treatment of heart failure","volume":"18","author":"Di","year":"2020","journal-title":"Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease"},{"key":"2026071707551047000_27.4.224.48","first-page":"132","article-title":"Effect of ivabradine on lipoprotein phospholipase A2 and cardiac function in heart failure patients with mid\u2043range ejection fraction","volume":"26","author":"Fu","year":"2021","journal-title":"Lingnan Journal of Emergency Medicine"},{"key":"2026071707551047000_27.4.224.49","first-page":"348","article-title":"Influence of ivabradine on 24-h heart rate, B-type natriuretic peptide and 6-minute walk distance in patients with acute decompensated systolic heart failure","volume":"9","author":"Gou","year":"2017","journal-title":"Chin J Evid Based Cardiovasc Med"},{"key":"2026071707551047000_27.4.224.50","first-page":"72","article-title":"The effect of heart rate control on cardiac function of patients with heart failure","volume":"8","author":"Guo","year":"2017","journal-title":"China Health Standard Management"},{"key":"2026071707551047000_27.4.224.51","first-page":"70","article-title":"The improvement of ventricular remodeling in patients with coronary heart disease and heart failure by ivabradine","volume":"25","author":"HT","year":"2019","journal-title":"Contemporary Medicine"},{"key":"2026071707551047000_27.4.224.52","first-page":"34","article-title":"Analysis on clinical curative effect of ivabradine in the treatment of chronic systolic heart failure","volume":"12","author":"CJ","year":"2017","journal-title":"Jiangsu Medicine"},{"key":"2026071707551047000_27.4.224.53","first-page":"1428","article-title":"Efficacy of ivabradine in treating acute myocardial infarction patients with heart failure","volume":"44","author":"SD","year":"2018","journal-title":"Jiangsu Medicine"},{"key":"2026071707551047000_27.4.224.54","first-page":"545","article-title":"The effect of ivabradine on the leve LS of cystatin C in elderly patients with chronic heart failure","volume":"16","author":"Huang","year":"2017","journal-title":"Chinese Journal Difficult and Complex cases"},{"key":"2026071707551047000_27.4.224.55","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ejhf.876","article-title":"Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial","volume":"19","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026071707551047000_27.4.224.56","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/eht308.1005","article-title":"Beneficial effect of If-channel inhibition on exercise tolerance in heart failure with preserved ejection fraction","volume":"34","author":"Kosmala","year":"2013","journal-title":"Eur Heart J"},{"key":"2026071707551047000_27.4.224.57","first-page":"129","article-title":"Effect of ivabradine combined with metoprolol in the treatment of chronic heart failure","volume":"14","author":"Li","year":"2020","journal-title":"Chin J Mod Drug Appl"},{"key":"2026071707551047000_27.4.224.58","first-page":"356","article-title":"Effect of sodium creatine phosphate combined with ivabradine in the treatment of chronic heart failure","volume":"30","author":"JP","year":"2018","journal-title":"Modern Practical Medicine"},{"key":"2026071707551047000_27.4.224.59","first-page":"77","article-title":"Effects of ivabradine combined with carvedilol on cardiac function, serum NT-pro BNP and Ang\u2161 levels in patients with chronic heart failure","volume":"37","author":"Li","year":"2020","journal-title":"J Sichuan Univ"},{"key":"2026071707551047000_27.4.224.60","first-page":"270","article-title":"Effect of ivabradine on plasma H2S and BNP in patients with chronic pulmonary heart disease and heart failure","volume":"34","author":"Liu","year":"2019","journal-title":"JNSMC"},{"key":"2026071707551047000_27.4.224.61","first-page":"34","article-title":"Clinical effect of ivabradine in the treatment of chronic systolic heart failure","volume":"36","author":"Liu","year":"2020","journal-title":"Chinese Community Doctors"},{"key":"2026071707551047000_27.4.224.62","first-page":"16","article-title":"Clinical effect of ivabradine in the treatment of heart failure with preserved ejection fraction\uff1aa randomized\uff0c double blind\uff0ccontrolled clinical study","volume":"28","author":"Liu","year":"2020","journal-title":"Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease"},{"key":"2026071707551047000_27.4.224.63","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.healun.2016.06.005","article-title":"Control of sinus tachycardia as an additional therapy in patients with decompensated heart failure (CONSTATHE-DHF): a randomized, double-blind, placebo-controlled trial","volume":"35","author":"Lofrano-Alves","year":"2016","journal-title":"J Heart Lung Transplant"},{"key":"2026071707551047000_27.4.224.64","unstructured":"Lu P . The effect of ivabradine on cardiac function and cardiac echocardiographic parameterss in patients with dilated cardiomyopathy. Yanbian University, 2019."},{"key":"2026071707551047000_27.4.224.65","first-page":"123","article-title":"Influence of ivabradine combined with levosimendan on ventricular remodeling in senile patients with chronic heart failure","volume":"17","author":"YH","year":"2020","journal-title":"Chin Med Her"},{"key":"2026071707551047000_27.4.224.66","first-page":"44","article-title":"Efficacy of Iavbredeen in treatment of very elderly patients with heart failure with mid-range ejection fraction","volume":"33","author":"Luo","year":"2021","journal-title":"Journal of SNAKE"},{"key":"2026071707551047000_27.4.224.67","first-page":"2156","article-title":"Effects of ivabradine on myocardial micro-circulation and levels of platelet parameters in patients with chronic pulmonary heart disease complicated with heart failure","volume":"19","author":"TL","year":"2020","journal-title":"Journal of Clinical and Experimental Medicine"},{"key":"2026071707551047000_27.4.224.68","unstructured":"Ma Z . Ivabradine bisulfate for patients with moderate to severe chronic heart failure andleft ventricular systolic dysfunction [Master Degree of Medicine. University of Jinan, 2016."},{"key":"2026071707551047000_27.4.224.69","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ehj.2011.09.001","article-title":"Efficacy of ivabradine in idiopathic dilated cardiomyopathy patients with chronic heart failure","volume":"63","author":"Mansour","year":"2011","journal-title":"Egypt Heart J"},{"key":"2026071707551047000_27.4.224.70","doi-asserted-by":"publisher","DOI":"10.1159\/000073933"},{"key":"2026071707551047000_27.4.224.71","first-page":"1017","article-title":"Effect of ivabradine on chronic heart failure and its effect on biomarkers","volume":"46","author":"Mao","year":"2018","journal-title":"Mod Med J"},{"key":"2026071707551047000_27.4.224.72","unstructured":"Masi De Luca G , Palmisano P , Zaccaria M . Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure. Circulation 2013:12816580."},{"key":"2026071707551047000_27.4.224.73","article-title":"Efficacy of ivabradine in patients with chronic heart failure after myocardial infarction","volume":"10","author":"Moiseev","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026071707551047000_27.4.224.74","article-title":"Intravenous ivabradine in low cardiac output syndrome after cardiac surgery treated by dobutamine: a phase II trial","volume":"10","author":"Nguyen","year":"2018","journal-title":"Arch Cardiovasc Dis Suppl"},{"key":"2026071707551047000_27.4.224.75","doi-asserted-by":"crossref","first-page":"501","DOI":"10.5603\/CJ.a2015.0012","article-title":"Effects of ivabradine therapy on heart failure biomarkers","volume":"22","author":"Ordu","year":"2015","journal-title":"Cardiol J"},{"key":"2026071707551047000_27.4.224.76","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.017119"},{"key":"2026071707551047000_27.4.224.77","first-page":"317","article-title":"Short-Term efficacy of ivabradine in patients with acute decompensated heart failure with reduced ejection fraction","volume":"35","author":"Pan","year":"2020","journal-title":"Clinical Focus"},{"key":"2026071707551047000_27.4.224.78","first-page":"19","article-title":"[Efficacy of ivabradin in combined treatment of patients with postinfarction systolic chronic cardiac failure]","volume":"83","author":"Potapenko","year":"2011","journal-title":"Ter Arkh"},{"key":"2026071707551047000_27.4.224.79","first-page":"740","article-title":"Study on effects of dibutyryl cyclic adenosine phosphate combined with ivabradine in the treatment of chronic heart failure","volume":"29","author":"Qi","year":"2019","journal-title":"Medical Journal of National Defending Forces in Southwest China"},{"key":"2026071707551047000_27.4.224.80","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ihj.2017.08.009","article-title":"Heart rate manipulation in dilated cardiomyopathy: assessing the role of ivabradine","volume":"70","author":"Raja","year":"2018","journal-title":"Indian Heart J"},{"key":"2026071707551047000_27.4.224.81","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2174\/1570161114666160505143003","article-title":"Impact of ivabradine on health-related quality of life of patients with ischaemic chronic heart failure","volume":"14","author":"Sallam","year":"2016","journal-title":"Curr Vasc Pharmacol"},{"key":"2026071707551047000_27.4.224.82","doi-asserted-by":"publisher","DOI":"10.1177\/1074248410370326"},{"key":"2026071707551047000_27.4.224.83","first-page":"526","article-title":"Effect of ivabradine in the treatment of senile heart failure and its influence on NTproBNP\uff0csST2 and galectin-3","volume":"21","author":"Shen","year":"2018","journal-title":"Practical Pharmacy And Clinical Remedies"},{"key":"2026071707551047000_27.4.224.84","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/AC.71.3.3152092","article-title":"Effect of selective heart rate reduction through sinus node If current inhibition on severely impaired left ventricular diastolic dysfunction in patients with chronic heart failure","volume":"71","author":"Sisakian","year":"2016","journal-title":"Acta Cardiol"},{"key":"2026071707551047000_27.4.224.85","first-page":"93","article-title":"Effect of ivabradine on cardiac function and plasma N-terminal brain natriuretic peptide in elderly patients with heart failure and asthenia syndrome","volume":"33","author":"Song","year":"2021","journal-title":"J West China"},{"key":"2026071707551047000_27.4.224.86","first-page":"1126","article-title":"Ivabradine hydrochloride tablets combined with metoprolol sustained-release tablets in the treatment of chronic heart failure","volume":"41","author":"DL","year":"2020","journal-title":"Jilin Med J"},{"key":"2026071707551047000_27.4.224.87","first-page":"5","article-title":"Clinial efficacy of ivabradine combined with Zhigancao decoction in the treatment of chronic heart failure","volume":"39","author":"DL","year":"2020","journal-title":"Inner Mongolia Journal of Traditional Chinese Medicine"},{"key":"2026071707551047000_27.4.224.88","first-page":"130","article-title":"Effect of clinical application of ivabradine combined with metoprolol in the treatment of chronic heart failure","volume":"16","author":"Sun","year":"2021","journal-title":"China Prac Med"},{"key":"2026071707551047000_27.4.224.89","first-page":"182","article-title":"Effect of ivabradine on chronic heart failure, B-type brain natriuretic peptide and N-terminal pro-B-type brain natriuretic peptide","volume":"15","author":"Sun","year":"2020","journal-title":"China Medicine"},{"key":"2026071707551047000_27.4.224.90","first-page":"407","article-title":"Analysis of efficacy and safety on ivabradine combined with \u03b2-receptor blockers in the early treatment of chronic heart failure","volume":"27","author":"Tang","year":"2018","journal-title":"Journal of Logistics University of PAP:Medical Sciences"},{"key":"2026071707551047000_27.4.224.91","article-title":"Clinical experience of treatment with ivabradine in patients with severe chronic heart failure","volume":"10","author":"Tarlovskaya","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026071707551047000_27.4.224.92","first-page":"40","article-title":"[Clinical efficacy of ivabradin and nebivolol addition in combined treatment of ischemic heart disease patients with left ventricular dysfunction]","volume":"80","author":"Tatarchenko","year":"2008","journal-title":"Ter Arkh"},{"key":"2026071707551047000_27.4.224.93","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1253\/circj.CJ-15-1112","article-title":"Heart Rate Control With If Inhibitor, Ivabradine, in Japanese Patients With Chronic Heart Failure\u3000- A Randomized, Double-Blind, Placebo-Controlled Phase II Study","volume":"80","author":"Tsutsui","year":"2016","journal-title":"Circ J"},{"key":"2026071707551047000_27.4.224.94","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1253\/circj.CJ-19-0227","article-title":"Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure\u3000- J-SHIFT Study","volume":"83","author":"Tsutsui","year":"2019","journal-title":"Circ J"},{"key":"2026071707551047000_27.4.224.95","article-title":"Comparative efficacy of carvedilol and ivabradine in severe chronic heart failure of ischemic origin with baseline heart rate below and above 70 beat per minute","volume":"30","author":"Tumasyan","year":"2009","journal-title":"Eur Heart J"},{"key":"2026071707551047000_27.4.224.96","article-title":"Efficacy of long-term ivabradine therapy in severe systolic chronic heart failure patients with and without type 2 diabetes mellitus","volume":"17","author":"Tumasyan","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026071707551047000_27.4.224.97","article-title":"Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved ejection fraction","volume":"19","author":"Tumasyan","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026071707551047000_27.4.224.98","article-title":"Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and mid-ranged ejection fraction","volume":"20","author":"Tumasyan","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026071707551047000_27.4.224.99","article-title":"Efficacy of ivabradine therapy on right heart parameters and prognosis in patients with severe systolic chronic heart failure","volume":"33","author":"Tumasyan","year":"2012","journal-title":"Eur Heart J"},{"key":"2026071707551047000_27.4.224.100","first-page":"672","article-title":"Efficacy of addition of ivabradine to bisoprolol in patients with essential hypertension, coronary artery disease and reduced left ventricular systolic function","volume":"36","author":"Vatinian","year":"2015","journal-title":"Eur Heart J"},{"key":"2026071707551047000_27.4.224.101","first-page":"30","article-title":"The efficacy of ivabradine in the treatment of patients with chronic heart failure","volume":"31","author":"Wang","year":"2019","journal-title":"Journal of Heze Medical College"},{"key":"2026071707551047000_27.4.224.102","first-page":"17790","article-title":"The effectiveness of ivabradine in elderly patients with chronic heart failure","volume":"4","author":"Wang","year":"2017","journal-title":"Journal Of Clinical Medicine"},{"key":"2026071707551047000_27.4.224.103","first-page":"437","article-title":"Study on the application value of ivabradine in vulnerable stage of heart failure","volume":"32","author":"Wang","year":"2020","journal-title":"Journal of SNAKE"},{"key":"2026071707551047000_27.4.224.104","first-page":"13823","article-title":"Clinical observation of ivabradine combined with metoprolol in the treatment of chronic heart failure","volume":"4","author":"Wang","year":"2017","journal-title":"Journal Of Clinical Medicine"},{"key":"2026071707551047000_27.4.224.105","first-page":"690","article-title":"Effects of levosimendan combined with ivabradine hydrochloride on heart function\uff0c myocardial fibrosis markers and exercise tolerance in patients with chronic heart failure","volume":"15","author":"Wang","year":"2020","journal-title":"Internal Medicine"},{"key":"2026071707551047000_27.4.224.106","first-page":"664","article-title":"Clinical effect of ivabradine in treatment of patients with chronic heart failure","volume":"53","author":"Wang","year":"2017","journal-title":"Acta Academiae Medicine QingDao University"},{"key":"2026071707551047000_27.4.224.107","first-page":"5","article-title":"Effect of ivabradine on ventricular rate control in heart failure vulnerable period","volume":"2","author":"Wang","year":"2017","journal-title":"Clinical Medical Research And Practice"},{"key":"2026071707551047000_27.4.224.108","first-page":"214","article-title":"Effects of ivabradine on cardiac function and NT-proBNP in patients with chronic heart failure","volume":"40","author":"Wang","year":"2018","journal-title":"Acta Acad Med Weifang"},{"key":"2026071707551047000_27.4.224.109","first-page":"33","article-title":"Clinical effect and adverse reactions of ivabradine in the treatment of chronic heart failure","volume":"4","author":"Wei","year":"2019","journal-title":"Clinical Research and Practice"},{"key":"2026071707551047000_27.4.224.110","first-page":"20","article-title":"Effects of ivabradine tablets on heart function and serum catecholamine level in patients with heart failure","volume":"25","author":"Xia","year":"2016","journal-title":"China pharmaceuticals"},{"key":"2026071707551047000_27.4.224.111","first-page":"112","article-title":"Clinical efficacy of ivabradine Hydrochlorid combined with metoprolol in patients with chronic heart failure","volume":"10","author":"Xing","year":"2018","journal-title":"China Continuing Medical Education"},{"key":"2026071707551047000_27.4.224.112","first-page":"40","article-title":"Effect of ivabradine on IL-6 and TNF-\u03b1 in patients with chronic heart failure","volume":"28","author":"Xu","year":"2019","journal-title":"Journal of Logistics University of PAP"},{"key":"2026071707551047000_27.4.224.113","first-page":"4932","article-title":"Efficacy of ivabradine combined with Shensong Yangxin capsule on elderly patients with chronic heart failure and its effect on lipid metabolism, brain natriuretic peptide and cardiac function","volume":"40","author":"YQ","year":"2020","journal-title":"Chinese Journal of Gerontology"},{"key":"2026071707551047000_27.4.224.114","first-page":"85","article-title":"The effect of ivabradine combined with metoprolol on heart rate variability and QT dispersion in patients with heart failure","volume":"10","author":"Xue","year":"2020","journal-title":"China Medicine and Pharmacy"},{"key":"2026071707551047000_27.4.224.115","first-page":"350","article-title":"Clinical effect of ivabradine and its influence on hemodynamics and vascular endothelial function in patients with chronic heart failure","volume":"29","author":"Yang","year":"2019","journal-title":"Chinese Journal of Health Laboratory Technology"},{"key":"2026071707551047000_27.4.224.116","first-page":"24","article-title":"Effectiveness of ivabradine in the treatment of acute myocardial infarction complicated with heart failure","volume":"31","author":"Yang","year":"2019","journal-title":"Chinese Journal of Urban and Rural Industrial Hygiene"},{"key":"2026071707551047000_27.4.224.117","unstructured":"Clinical efficacy of ivabradine in the treatment of chronic systolic heart failure. \"Emergency Medicine Clinical Academic Research Conference\" meeting; 2016; Beijing."},{"key":"2026071707551047000_27.4.224.118","first-page":"1030","article-title":"Effect of ivabradine on cardiac function and heart rate variability of ischemic cardiomyopathy patients","volume":"15","author":"RX","year":"2017","journal-title":"Chinese Journal ofCardiovascular Research"},{"key":"2026071707551047000_27.4.224.119","first-page":"197","article-title":"Analysis of the application of ivabradine in the treatment of chronic heart failure","volume":"15","author":"Yu","year":"2018","journal-title":"Particularly Healthy"},{"key":"2026071707551047000_27.4.224.120","first-page":"69","article-title":"Effects of ivabradine in the patients with chronic heart failure resulting from dilated cardiomyopathy","volume":"10","author":"XB","year":"2019","journal-title":"China Health Standard Management"},{"key":"2026071707551047000_27.4.224.121","unstructured":"Yue LB . Efficacy and safety of ivabradine sustained-release tablets in the treatment of elderly patients with chronic heart failure [master degree of medicine]. University of Jinan, 2016."},{"key":"2026071707551047000_27.4.224.122","first-page":"168","article-title":"Effectiveness of ivabradine in the treatment of chronic heart failure with sinus tachycardia","volume":"14","author":"Zeng","year":"2019","journal-title":"Chinese Journal of Misdiagnosis"},{"key":"2026071707551047000_27.4.224.123","first-page":"2740","article-title":"Effects of ivabradine in the treatment of chronic heart failure and its influence on serum GDF-15 and sst2 levels in patients","volume":"30","author":"Zeng","year":"2019","journal-title":"Hainan Medical Journal"},{"key":"2026071707551047000_27.4.224.124","first-page":"1471","article-title":"Effect of ivabradine in the treatment of acute exacerbation of chronic obstructive pulmonary disease with heart failure","volume":"25","author":"Zhang","year":"2019","journal-title":"Journal of Hainan Medical University"},{"key":"2026071707551047000_27.4.224.125","first-page":"59","article-title":"Effects of ivabradine on cardiac function and serum Galectin-3\uff0csST2 and NT-proBNP levels in patients with chronic heart failure","volume":"24","author":"Zhang","year":"2021","journal-title":"Chin J Clin Healthc"},{"key":"2026071707551047000_27.4.224.126","first-page":"256","article-title":"Clinical effect of ivabradine on coronary heart disease combined with chronic obstructive pulmonary disease","volume":"48","author":"Zhang","year":"2019","journal-title":"Shaanxi Medical Journal"},{"key":"2026071707551047000_27.4.224.127","first-page":"1247","article-title":"Effect of ivabradine combined with low-dose metoprolol tartrate in patients with chronic heart failure","volume":"28","author":"Zhang","year":"2019","journal-title":"Henan Medical Research"},{"key":"2026071707551047000_27.4.224.128","first-page":"134","article-title":"Analysis of clinical effect of ivabradine in adjuvant treatment of patients with chronic heart failure","volume":"32","author":"Zhang","year":"2020","journal-title":"Strait Pharmaceutical Journal"},{"key":"2026071707551047000_27.4.224.129","first-page":"11","article-title":"Effect of ivabradine combined with metoprolol on cardiac function and carotid intima-media thickness of patients with coronary heart disease complicated with heart failure","volume":"32","author":"Zhang","year":"2020","journal-title":"Medical Journal of Chinese People\u2019s Health"},{"key":"2026071707551047000_27.4.224.130","first-page":"285","article-title":"The effect of ivabradine combined with levosimendan for treating chronic heart failure","volume":"30","author":"Zhao","year":"2020","journal-title":"China Health Care & Nutrition"},{"key":"2026071707551047000_27.4.224.131","first-page":"460","article-title":"Effects of metoprolol combined with ivabradine on cardiac function in patients with severe heart failure complicated with sinus tachycardia","volume":"20","author":"Zhou","year":"2020","journal-title":"Cardio-Cerebrovasc Dis Prev Treat"},{"key":"2026071707551047000_27.4.224.132","unstructured":"Zhou Y . The effects of ivabradine on the heart rate variability and cardiac structure and function in chronic heart failure patients with mild-range ejection fraction. Southwest Medical University, 2019."},{"key":"2026071707551047000_27.4.224.133","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.01.013"},{"key":"2026071707551047000_27.4.224.134","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfp154"},{"key":"2026071707551047000_27.4.224.135","unstructured":"Servier . Effects of ivabradine on cardiovascular events in patients with moderate to severe chronic heart failure and left ventricular systolic dysfunction. A three-year international multicentre study (shift) ClinicalTrials2015. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02441218 [Accessed 24 Feb 2020]."},{"key":"2026071707551047000_27.4.224.136","unstructured":"Servier . The beautiful study: effects of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction ClinicalTrials2005. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00143507 [Accessed 24 Feb 2020]."},{"key":"2026071707551047000_27.4.224.137","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr343"},{"key":"2026071707551047000_27.4.224.138","article-title":"Ivabradine improves physical performance and neurohormonal parameters in patients with diastolic heart failure","volume":"128","author":"De Luca","year":"2013","journal-title":"Circulation"},{"key":"2026071707551047000_27.4.224.139","article-title":"Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and preserved ejection fraction","volume":"19","author":"Liana Tumasyan","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026071707551047000_27.4.224.140","article-title":"Comparative efficacy of long-term digoxin and ivabradine therapy on prognosis, left and right heart functional parameters in patients with chronic heart failure and mid-ranged ejection fraction","volume":"20","author":"Liana Tumasyan","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026071707551047000_27.4.224.141","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39465.451748.AD"},{"key":"2026071707551047000_27.4.224.142","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520290060030"},{"key":"2026071707551047000_27.4.224.143","doi-asserted-by":"publisher","DOI":"10.3310\/hta16150"},{"key":"2026071707551047000_27.4.224.144","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)01085-X"},{"key":"2026071707551047000_27.4.224.145","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-11-200112040-00010"},{"key":"2026071707551047000_27.4.224.146","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwj069"},{"key":"2026071707551047000_27.4.224.147","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2020-001288"}],"container-title":["BMJ Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjebm-2021-111724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:55:51Z","timestamp":1784300151000},"score":1,"resource":{"primary":{"URL":"https:\/\/ebm.bmj.com\/lookup\/doi\/10.1136\/bmjebm-2021-111724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":147,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,7,28]]},"published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1136\/bmjebm-2021-111724"],"URL":"https:\/\/doi.org\/10.1136\/bmjebm-2021-111724","relation":{},"ISSN":["2515-446X","2515-4478"],"issn-type":[{"value":"2515-446X","type":"print"},{"value":"2515-4478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]}}}